Still Mulling EUA Transition Options? Don’t Wait Too Long, Attorney Says

Manufacturers whose COVID-19 related products reached market via the US FDA emergency use authorization pathway will soon face a choice as to whether to get additional clearances stay on the market or not. According to Alston and Bird attorney Ben Wolf, the time to prepare is now.